BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24772479)

  • 1. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
    Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
    Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
    Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
    Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
    Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
    Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
    Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
    Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
    Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
    Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
    Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
    Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
    Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
    Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
    Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.
    Wilkinson K; Velloso ER; Lopes LF; Lee C; Aster JC; Shipp MA; Aguiar RC
    Blood; 2003 Dec; 102(12):4187-90. PubMed ID: 12907457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
    Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
    Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
    Gallagher G; Horsman DE; Tsang P; Forrest DL
    Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
    Cheah CY; Burbury K; Apperley JF; Huguet F; Pitini V; Gardembas M; Ross DM; Forrest D; Genet P; Rousselot P; Patton N; Smith G; Dunbar CE; Ito S; Aguiar RC; Odenike O; Gimelfarb A; Cross NC; Seymour JF
    Blood; 2014 Jun; 123(23):3574-7. PubMed ID: 24687085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
    David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
    Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
    Baxter EJ; Kulkarni S; Vizmanos JL; Jaju R; Martinelli G; Testoni N; Hughes G; Salamanchuk Z; Calasanz MJ; Lahortiga I; Pocock CF; Dang R; Fidler C; Wainscoat JS; Boultwood J; Cross NC
    Br J Haematol; 2003 Jan; 120(2):251-6. PubMed ID: 12542482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.
    Yamazaki M; Nakaseko C; Takeuchi M; Ozawa S; Ishizuka Y; Hatanaka Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Ohwada C; Takeda Y; Mimura N; Iseki T; Fukazawa M; Sakaida E
    Intern Med; 2019 Dec; 58(23):3449-3453. PubMed ID: 31327842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].
    Zhang XY; Liu TF; Li CW; Li QH; Zhu XF
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.
    Xu X; Lu Q; Wang Z; Cai P; Zeng Z; Zhang L; Wang M; Ma L; Ruan C; Chen S
    Cancer Res Treat; 2021 Jul; 53(3):889-892. PubMed ID: 33421986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
    Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.